Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BILATIME-M
- Development stage
- Unknown
- Lead developer
- Intra Life
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BILATIME-M is a fixed-dose combination oral tablet developed by Intra Life, combining the second-generation H1 antihistamine bilastine with the leukotriene receptor antagonist montelukast. Bilastine works by selectively blocking peripheral histamine H1 receptors, thereby alleviating symptoms such as sneezing, itching, and rhinorrhea. Montelukast targets the cysteinyl leukotriene receptor 1 (CysLT1), inhibiting the action of leukotrienes that cause bronchoconstriction and allergic inflammation. This dual-action approach provides comprehensive relief for upper and lower respiratory symptoms associated with allergic rhinitis and chronic urticaria. The product is marketed in various strengths, including pediatric formulations (10mg bilastine / 4mg montelukast) and adult formulations (20mg/10mg or 40mg/10mg).
- Brand names
- BILATIME-MBILATIME-M-40BILATIME-M40BILATIME-M 40
- Other names
- bilastine + montelukastmontelukast + bilastine
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on BILATIME-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BILATIME-M.